[
  {
    "argument": "When the FDA rejects a manufacturer\u2019s proposal to warn about a disclosed risk, the manufacturer cannot be penalized for failing to warn of that risk",
    "type": "petitioner",
    "sub_arguments": [
      {
        "argument": "Failure-to-warn claims are preempted if federal law would have forbidden the manufacturer to revise its label"
      },
      {
        "argument": "Where the FDA rejects a request to add a warning, failure-to-warn claims are preempted"
      },
      {
        "argument": "Respondents\u2019 failure-to-warn claims are preempted"
      }
    ]
  },
  {
    "argument": "The third CIRCUIT misunderstood LEVINE and the regulatory scheme",
    "type": "petitioner",
    "sub_arguments": [
      {
        "argument": "The fda\u2019s real-world action here eliminates the need for counterfactual inquiry"
      },
      {
        "argument": "The third circuit\u2019s approach also led it astray in other ways"
      }
    ]
  },
  {
    "argument": "In light of the fda\u2019s position here, MERCK must prevail",
    "type": "petitioner",
    "sub_arguments": []
  },
  {
    "argument": "Failure-to-warn claims against brand-name drug manufacturers are not preempted unless the manufacturer shows by clear evidence that FDA would have rescinded an adequate label change",
    "type": "respondent",
    "sub_arguments": [
      {
        "argument": "The FDCA does not expressly preempt failure-to-warn claims against brand-name drug manufacturers, and such claims pose no obstacle to the statute\u2019s purposes"
      },
      {
        "argument": "A brand-name drug manufacturer has the power to strengthen a drug label to comply with state law"
      },
      {
        "argument": "The 2007 FDCA amendments do not preempt state law"
      }
    ]
  },
  {
    "argument": "Merck has not shown by clear evidence that FDA would have rescinded an adequate warning of atypical femoral fractures",
    "type": "respondent",
    "sub_arguments": [
      {
        "argument": "The complete response letter regarding merck\u2019s proposed stress-fracture warning did not preclude MERCK from adding an adequate warning of atypical femoral fractures",
        "sub_arguments": [
          {
            "argument": "Merck never proposed an accurate warning of atypical femoral fractures",
            "sub_arguments": []
          },
          {
            "argument": "The complete response letter did not preclude MERCK from adding an adequate warning of atypical femoral fractures through a CBE supplement",
            "sub_arguments": []
          },
          {
            "argument": "The government\u2019s post hoc interpretations of the complete response letter are implausible and inconsistent with FDA regulations",
            "sub_arguments": []
          }
        ]
      },
      {
        "argument": "Merck\u2019s informal communications with FDA do not establish preemption"
      },
      {
        "argument": "Fda\u2019s decision to mandate an atypical-femoral-fracture warning undercuts merck\u2019s preemption defense"
      }
    ]
  },
  {
    "argument": "The third circuit\u2019s guidance for the district court on remand was correct",
    "type": "respondent",
    "sub_arguments": [
      {
        "argument": "A jury should resolve disputed factual questions necessary for preemption"
      },
      {
        "argument": "The third CIRCUIT correctly required a heightened standard of proof for impossibility preemption under LEVINE"
      },
      {
        "argument": "Granting summary judgment would violate respondents\u2019 procedural rights"
      }
    ]
  }
]